Aurinia Pharmaceuticals

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aurinia Pharmaceuticals reports robust Q4 earnings and navigates growth challenges

Aurinia Pharmaceuticals had a strong Q4 performance, with revenue growth and patient access milestones. Despite challenges from COVID-19 and legal disputes, the company remains financially stable and focused on driving growth through patient-centric strategies. Opportunities lie in improving patient adherence and expanding market reach.

Aurinia Pharmaceuticals reports strong Q1 performance and eyes global expansion

Aurinia Pharmaceuticals delivered robust financial performance in Q1 2023, with strong revenue growth and positive patient outcomes.
The company's strategic initiatives and globalization efforts position it well for future growth and market expansion.
Challenges such as slowing new patient starts and persistency caution require focused attention for sustained success.
Opportunities lie in enhancing patient engagement, driving revenue through new patient starts, and strengthening competitive positioning.

Aurinia Pharmaceuticals excels in Q2 earnings, eyes growth opportunities

Aurinia Pharmaceuticals delivered strong financial results in Q2 2023, driven by revenue growth, improved commercial metrics, and effective cost management.
The company's focus on patient awareness, clinical differentiation, and market access for LUPKYNIS positions it well in the competitive landscape of lupus nephritis treatment.
While facing challenges such as seasonality impact and strategic uncertainties, Aurinia remains optimistic about its financial stability, pipeline progress, and growth opportunities.

Aurinia Pharmaceuticals reports strong Q3 performance and explores growth

Aurinia Pharmaceuticals demonstrated robust financial performance and strategic partnerships in Q3 2023, positioning itself for future growth.
While facing challenges in persistency rates and strategic decision-making, the company is leveraging upcoming guidelines and data submissions for market advantage.
Opportunities in education, regulatory approvals, and pricing strategies present avenues for sustained growth and market expansion in the lupus nephritis segment.

Aurinia Pharmaceuticals reports strong Q1 earnings and growth opportunities

Aurinia Pharmaceuticals delivered a robust performance in Q1 2024, driven by strong revenue growth and strategic cost management.
While facing challenges in managing expenses and optimizing patient outcomes, the company remains well-positioned for future profitability.
With a focus on expanding market access, enhancing treatment guidelines, and leveraging its financial strength, Aurinia is poised for continued growth and success.

Aurinia Pharmaceuticals reports robust Q2 revenue growth and strategic initiatives

Aurinia Pharmaceuticals delivered strong financial performance in Q2 2024, with notable revenue growth and operational efficiency.
While facing challenges in revenue guidance and market expectations, the company's strategic initiatives and product adoption present growth opportunities.
With a focus on product development, market expansion, and patient engagement, Aurinia is poised for continued success in the pharmaceutical industry.

Aurinia Pharmaceuticals reports robust Q3 earnings and strategic milestones

Aurinia Pharmaceuticals delivered impressive financial results in Q3 2024, showcasing growth in revenue and operational efficiency.
Despite undergoing a significant restructuring, the company remains focused on innovation, achieving milestones, and expanding its market presence.
With a strong cash position and strategic outlook, Aurinia is poised for continued success and growth in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees.

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Two of Aurinia's largest shareholders wrote tough letters against the AUPH board, leading to two resignations. One of these shareholders also wanted AUPH to sell out.

Aurinia: Despite Milder Shareholder Vote, A Bid To Sell Is Still Not Over

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia's outstanding shares, today commented on the outcome of the Company's 2023 Annual General Meeting of Shareholders (the “Annual Meeting”) held on May 17, 2023. At the Annual Meeting, Chairman George Milne and Compensation Committee Ch.

MKT Capital Thanks Fellow Shareholders for Their Strong Support at Aurinia's 2023 Annual Meeting

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces 2023 Annual General Meeting Results.

Aurinia Announces 2023 Annual General Meeting Results

Does Aurinia Pharmaceuticals (AUPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Aurinia Pharmaceuticals (AUPH) is a Great Momentum Stock to Buy

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”) is a significant shareholder of Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia's outstanding shares. Today, MKT Capital commented on the filing by the Company's largest shareholder, Iljin SNT Co., Ltd. (together with its affiliates, “Iljin”), stating its intention to WITHHOLD support for Chairman Dr. George.

MKT Capital Comments on Aurinia's Largest Shareholder's Plans to WITHHOLD Support for the Majority of the Board at the 2023 Annual Meeting

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced data from the kidney biopsy sub-study of the AURORA clinical trial program (AURORA 1 and AURORA 2 Extension Study) was presented at the Congress of Clinical Rheumatology East Conference May 4 – 7, 2023. The addition of LUPKYNIS to standard of care MMF and low-dose steroids in Aurinia's Phase 3 AURORA program led to significantly earlier and greater reductions in proteinuria w.

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia's outstanding shares, today issued a statement regarding the Company's recently issued financial results for the quarter ended March 31, 2023. As a reminder, MKT Capital is recommending shareholders WITHHOLD support for Chairman Dr.

MKT Capital Issues Statement Regarding Aurinia's Disappointing First Quarter 2023 Financial Results

Start Time: 08:30 January 1, 0000 9:27 AM ET Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and CEO Joe Miller - CFO Jamie Harrell - Head of IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Farzin Haque - Jefferies Stacy Ku - TD Cowen Justin Kim - Oppenheimer Ed Arce - H.C. Wainwright David Martin - Bloom Burton Will Soghikian - SVB Securities Sahil Dhingra - RBC Capital Markets Operator Greetings, and welcome to Aurinia Pharmaceuticals Inc. First Quarter 2023 Earnings Call.

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Call Transcript

EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS.

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial ownership of approximately 4.2% of Aurinia's outstanding shares, today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, has recommended shareholders vote AGAINST the ratification of the Company's named executive office.

ISS Recommends Aurinia Shareholders Vote Against the Company's Named Executive Officers' Compensation

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis.

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis

EDMONTON, Alberta--(BUSINESS WIRE)--ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting.

ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual General Meeting

EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA PHARMACEUTICALS ANNOUNCES SWISSMEDIC APPROVAL OF LUPKYNIS® (VOCLOSPORIN).

Aurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)

EDMONTON, Alberta--(BUSINESS WIRE)--Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting.

Glass Lewis Recommends Aurinia Shareholders Vote “FOR” ALL Company Director Nominees at 2023 Annual Meeting

Amylyx Pharmaceuticals

Madrigal Pharmaceuticals

With multiple blockbuster drugs going off patent this decade, pharma companies are expected to ratchet up their M&A activities. These three companies sport high-value assets that could attract suitors soon.

3 Biotechs That Might Get Bought Out in 2023

MKT Capital, which owns a 4.2% stake in Aurinia Pharmaceuticals (TSX:AUP) Inc, wrote in a letter to shareholders on Monday that the company should put itself up for sale, believing the biopharmaceutical firm could be worth up to $28 per share, equivalent to a 192% premium to its current stock price. MKT, meanwhile, expressed its disappointment in decisions made by the current board, especially the compensation committee's 2020 decision to reward CEO Peter Greenleaf with a $10.7 million pay package despite the poor performance of Aurinia's stock price.

Aurinia Pharmaceuticals shareholder says sale could reward investors with nearly 200% gain

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd., a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) which together with its affiliates beneficially owns approximately 4.2% of Aurinia's outstanding shares, today issued the following letter to the Company's shareholders. *** Fellow Shareholders, MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”) is a significant shareholder of Aurinia Pharmaceuticals Inc. (“Aurinia” or the “.

MKT Capital Issues Letter to Aurinia Shareholders Announcing its Intention to Withhold Support for Three Directors at 2023 Annual Meeting

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023.

Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023

Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.

Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent

Aurinia Pharmaceuticals' stock is continuing its recent upward movement today. Investors are piling into the stock following a new patent for the company's lupus nephritis medication.

Why Aurinia Pharmaceuticals Stock Is Glowing Green Today

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia's newly issued U.S. Patent (No. 11,622,991) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS.

Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office

Medtronic

Reata Pharmaceuticals

Reata Pharmaceuticals earned approval for its first drug in February, and its stock price has been soaring ever since. The first new drug Aurinia Pharmaceuticals launched got off to a rocky start, but a strong end to 2022 caused the stock to soar this year, Orchestra BioMed is a medical technology developer that has an important partnership with Medtronic, the world's largest medical device manufacturer.

3 Stocks That Already Doubled in 2023 and Could Keep Climbing

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced promising results from the AURORA Renal Biopsy Sub-Study. LUPKYNIS is a novel agent approved for the treatment of adults with active lupus nephritis (LN).

Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

News for Aurinia Pharmaceuticals Stock (AUPH)